How India Exports Diltiazem to the World

In the United States, diltiazem is approved under multiple Abbreviated New Drug Applications (ANDAs). For instance, Mylan Pharmaceuticals received approval for diltiazem hydrochloride extended-release capsules (ANDA 75-124) on March 18, 1998. Additionally, Zydus Pharmaceuticals (USA) Inc. was granted approval for Tiadylt ER (diltiazem hydrochloride extended-release capsules) on June 22, 2017. These approvals indicate a well-established generic market for diltiazem in the U.S. The significant export volume from India to the U.S. underscores the importance of compliance with FDA regulations, including adherence to Current Good Manufacturing Practices (cGMP) and ensuring bioequivalence to the reference listed drug.

In the European Union, diltiazem is authorized for marketing through national procedures. The European Medicines Agency (EMA) conducted a periodic safety update report single assessment (PSUSA) for diltiazem, resulting in a variation to the terms of the marketing authorization in March 2023. (ema.europa.eu) In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) has managed the licensing of diltiazem products, with records indicating approvals dating back to May 9, 1994. (gov.uk) Compliance with EU Good Manufacturing Practice (GMP) guidelines is mandatory for manufacturers exporting to these markets.

Diltiazem is included in the World Health Organization's Model List of Essential Medicines, highlighting its importance in global health. The drug is recognized in various pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality and efficacy across different regions.

In India, diltiazem is classified under Schedule H of the Drugs and Cosmetics Act, requiring a prescription for dispensing. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines, including diltiazem, to ensure affordability. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of pharmaceutical products, ensuring compliance with national regulations.

The primary patents for diltiazem have expired, leading to a competitive generic market. This has facilitated the entry of multiple manufacturers, including Indian exporters, into global markets.

In March 2023, the EMA issued a variation to the marketing authorization for diltiazem following a periodic safety update report assessment. (ema.europa.eu) In April 2022, the MHRA released information regarding the licensing history and status of diltiazem products in the UK. (gov.uk) These developments underscore the dynamic regulatory environment surrounding diltiazem, necessitating continuous monitoring by exporters to ensure compliance with international standards.

India's pharmaceutical industry, including the production of Diltiazem, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of these critical components are sourced from China, underscoring a significant dependency. This reliance exposes the supply chain to risks associated with geopolitical tensions, trade restrictions, and production disruptions in China.

In October 2025, the U.S. Pharmacopeia highlighted that 58% of KSMs used for U.S.-approved APIs are solely sourced from a single country, predominantly China. Such concentration increases vulnerability to supply chain disruptions, which can lead to shortages and impact global pharmaceutical manufacturing, including India's Diltiazem production.

Our proprietary trade data from 2022 to 2026 indicates that the top five Indian exporters of Diltiazem account for 59.0% of total exports, with EMCURE PHARMACEUTICALS LIMITED leading at an 18.0% share. This concentration suggests a moderate risk, as disruptions affecting these key suppliers could significantly impact global Diltiazem availability.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic API and KSM production. While this initiative is a positive step toward reducing dependency on imports, its full impact on diversifying the supplier base and enhancing supply chain resilience remains to be seen.

The closure of the Strait of Hormuz since February 28, 2026, due to escalating conflicts involving Iran, the United States, and Israel, has severely disrupted global shipping routes. This strategic chokepoint is vital for maritime trade, and its blockade has led to significant delays and increased shipping costs. (lemonde.fr) Major shipping lines have suspended operations in the region, further exacerbating supply chain challenges.

Additionally, tensions in the Red Sea and the Strait of Hormuz have compelled shipping companies to reroute vessels, leading to longer transit times and higher operational costs. These disruptions pose a substantial risk to the timely export of Diltiazem from India to key markets, including the United States and Canada.

• Diversify API and KSM Sources: Encourage the development of alternative suppliers in different regions to reduce dependency on a single country, thereby enhancing supply chain resilience.

• Strengthen Domestic Production: Accelerate the implementation and scaling of the PLI scheme to bolster domestic manufacturing capabilities for APIs and KSMs, reducing reliance on imports.

• Enhance Supplier Due Diligence: Conduct comprehensive assessments of suppliers' financial health, operational capacity, and geopolitical exposure to identify and mitigate potential risks.

• Develop Contingency Logistics Plans: Establish alternative shipping routes and logistics strategies to navigate around disrupted areas like the Strait of Hormuz, ensuring continuity in export operations.

• Monitor Geopolitical Developments: Implement a robust monitoring system to stay informed about geopolitical events that could impact supply chains, enabling proactive risk management.

RISK_LEVEL: HIGH